- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04850521
Remote Monitoring of Interstitial Lung Disease
Remote Monitoring of Interstitial Lung Disease to Provide Continuity of Care and Shielding From Risks Associated With In-clinic Assessment
As in-clinic pulmonary function testing is greatly restricted due to Coronavirus Disease 2019 (COVID19), alternative approaches to monitoring patients with long-term respiratory conditions need to be developed and assessed. This project will evaluate the feasibility of a remote monitoring programme designed for interstitial lung disease (ILD) [including idiopathic pulmonary fibrosis (IPF)] patients which includes patient-reported spirometry & pulse oximetry (to estimate lung airflow and oxygen levels in the blood).
Patients with a confirmed diagnosis of ILD will be asked to measure spirometry & pulse oximetry once/day for approximately three months. Each patient will be supplied with a spirometer & pulse oximeter for home use. There will be no other changes to patients' care. The clinical teams responsible for care of the patients will be able to view all patient-recorded data immediately after data are recorded by the patient. Feasibility of remote monitoring will be assessed by determining the proportion of patients who provide measurements at least 3 times/week and on at least 70% of days in the observation period. Patient engagement (Patient Activation Measure), changes in spirometry measurements over time and healthcare resource utilisation (e.g. number of in-clinic visits) will also be assessed. Other outcomes assessed will include estimation of the proportion of patients with significant decreases in lung function, number of occasions where critical alert values of physiological parameters are reported and number of interventions by healthcare professionals in response to observations or alerts from remote monitoring. Feedback from patients and healthcare providers on user experience will also be sought.
Learnings from this project will be used to assess the wider application of delivery of digitally-based remote monitoring in management of long-term respiratory conditions.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Basingstoke, Royaume-Uni
- Hampshire Hospitals NHS Foundation Trust
-
London, Royaume-Uni
- Imperial College NHS Healthcare Trust
-
Nottingham, Royaume-Uni
- Nottingham University Hospitals Nhs Trust
-
Preston, Royaume-Uni
- Lancashire Teaching Hospitals NHS Foundation Trust
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- diagnosis of interstitial lung disease
- Forced Vital Capacity ≥50% predicted (at most recent in-clinic spirometry test)
- owns a smartphone or tablet device
- has a mobile telephone number, email address and access to internet at home
- willing to allow home monitoring of their health including spirometry and pulse oximetry data
- understands how to use mobile technology (e.g. has downloaded and used other "apps" on their mobile device; uses email)
- demonstrates willingness to measure spirometry and pulse oximetry daily for the duration of the study
- fluent in English language
- Written informed consent.
Exclusion Criteria:
- serious concomitant conditions which place the patient at high risk of respiratory distress, making them unsuitable to be managed at home
- confusion which would limit the patient's understanding of the project or the measurement procedures
- current or recent (within last 6 weeks before baseline) participation in another clinical research project.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Remote monitoring
Remote monitoring software + connected devices
|
patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Frequency of use ≥3 days/week
Délai: 90 days
|
Proportion of patients recording measurements ≥3 days/week
|
90 days
|
Frequency of use on ≥70% of study days
Délai: 91 days
|
Proportion of patients recording measurements on ≥70% of study days
|
91 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Health-related quality of life
Délai: 91 days
|
EuroQol 5-dimension 5-level (EQ-E5-DL) health status
|
91 days
|
Patient engagement
Délai: 91 days
|
Patient Activation Measure
|
91 days
|
Change in Forced Vital Capacity (FVC)
Délai: 91 days
|
Proportion of patients with ≥10% decreased FVC vs. baseline
|
91 days
|
Frequency of patients with alert values of pulse oximetry oxygen saturation (SpO2)
Délai: 91 days
|
Proportion of patients with pulse oximetry SpO2 <93% at any time
|
91 days
|
Frequency of alert values of pulse oximetry SpO2 per patient
Délai: 91 days
|
Number of pulse oximetry SpO2 <93% values per patient
|
91 days
|
Adherence to study measurements
Délai: 91 days
|
Number of days patients record spirometry/number of days in observation period
|
91 days
|
Frequency of use ≥1 day/week
Délai: 91 days
|
Proportion of patients recording measurements ≥1 day/week
|
91 days
|
Frequency of use ≥5 days/week
Délai: 91 days
|
Proportion of patients recording measurements ≥5 days/week
|
91 days
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time reviewing remote data
Délai: 91 days
|
Clinic time reviewing portal data/patient
|
91 days
|
Clinic/patient contacts
Délai: 91 days
|
Number of clinic center contacts with patient
|
91 days
|
Clinic spirometry visits
Délai: 91 days
|
Number of in-clinic spirometry visits
|
91 days
|
Hospital admissions
Délai: 91 days
|
Number of hospital admissions
|
91 days
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ILD patientMpower 01
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Remote monitoring
-
Centre d'Investigation Clinique et Technologique...ComplétéMaladie neuromusculaire | Ventilation mécanique domestiqueFrance
-
Universitätsmedizin MannheimComplétéImmuno-monitoringAllemagne
-
Sun Yat-sen UniversityHangzhou Repugene Technology Co., Ltd.RecrutementCancer du poumon non à petites cellulesChine
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaComplétéDiabète sucré, type 1Italie
-
Sun Yat-sen UniversityComplété
-
Yale UniversityComplété
-
The Hong Kong Polytechnic UniversityComplétéAppareil inefficaceHong Kong
-
University College CorkOsypka Medical, Berlin, GermanyRésiliéHémorragie intraventriculaire | Instabilité hémodynamique | Hypotension et choc | Hypoperfusion | Fonction cardiaque | Transition circulatoireIrlande
-
Lille Catholic UniversityInconnueLa dépression | Sclérose en plaquesFrance
-
Singapore General HospitalKK Women's and Children's Hospital; SingHealth PolyclinicsComplété